免疫抑制治疗与活检状态对疑似心脏结节病治疗反应监测的影响
本研究分析83例疑似心脏结节病患者,基线FDG-PET/CT示心肌摄取,治疗后复查PET评估完全/部分/无反应。71%达完全或部分反应,中等剂量泼尼松起始与更佳反应相关;活检确诊及左室功能保留者不良事件更少,治疗反应状态与结局无显著差异。
要点
- 连续FDG-PET/CT可用于评估疑似心脏结节病免疫抑制治疗后的心肌炎症反应。
- 中等剂量泼尼松起始较高剂量更与完全/部分治疗反应相关,高剂量组减量更快。
- 活检确诊和左室功能保留者随访中主要不良心脏事件风险更低。
关键影像表现/征象
- 基线FDG-PET/CT显示心肌氟脱氧葡萄糖摄取,提示活动性心肌炎症。
- 治疗后复查PET/CT视觉分级为完全治疗反应、部分治疗反应或无反应。
- 总糖酵解活性定量与视觉评估部分/无反应一致性极好(κ=0.86,95%CI 0.72-0.99,P<0.0001)。
诊断标准与关键数值
- 完全治疗反应为视觉分级心肌FDG摄取完全消失;部分/无反应同时采用视觉和总糖酵解活性定量评估。
- 71%患者(59/83)在随访扫描达完全或部分反应(完全30%、部分41%,P=0.04)。
临床应用与阅片要点
- 报告应明确心肌FDG摄取范围与程度变化,并给出完全/部分/无反应的视觉分级。
- 可结合总糖酵解活性定量辅助视觉评估,两者一致性高。
- 需结合泼尼松起始剂量及减量速度解释治疗反应,高剂量快速减量可能影响反应评估。
- 活检确诊状态和左室收缩功能可辅助风险分层,但治疗反应状态与不良事件无显著相关。
局限性
- 单中心回顾性设计,样本量83例,可能存在选择偏倚。
- 治疗反应状态与主要不良心脏事件无显著相关(P=0.23),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with suspected cardiac sarcoidosis frequently undergo fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging to assess disease activity at baseline and after treatment initiation.
OBJECTIVES: This study investigated the effect of immunosuppressive therapy and biopsy status to achieve complete treatment response (CTR), partial treatment response (PTR), or no response (NR) on myocardial FDG-PET/CT.
METHODS: This study analyzed 83 patients with suspected cardiac sarcoidosis (aged 53 ± 1.8 years, 71% were male, 69% were White, 61% had a history of biopsy-confirmed sarcoidosis) who were treatment naive, had evidence of myocardial FDG at baseline, and underwent repeat PET imaging after treatment initiation. CTR was graded visually, and PTR/NR were measured both visually and quantitatively using the total glycolytic activity. Patients were also evaluated for the occurrence of death, sustained ventricular arrhythmias, and heart failure admissions.
RESULTS: Overall, 59 patients (71%) achieved CTR/PTR (30%/41%) at follow-up scan (P = 0.04). Total glycolytic activity and visual estimate of PTR/NR had excellent agreement (κ = 0.86 [95% CI: 0.72-0.99]; P < 0.0001). In patients receiving prednisone only, the highest rates of CTR/PTR were observed in patients initiated on moderate or high dose (P < 0.01). In a regression model, moderate prednisone start dose (P = 0.03) was more strongly associated with achieving CTR/PTR than was high prednisone start dose. However, the latter patients were tapered faster between start dose and follow-up scan (P < 0.01). After a median follow-up of 4.7 (IQR: 3.1-7.8) years, patients who were biopsy-proven (vs non-biopsy-proven; P = 0.029) and with preserved left ventricular function (P = 002) were less likely to experience major adverse cardiac events. Outcomes based on treatment response status (CTR vs PTR vs NR; P = 0.23) were not significantly different.
CONCLUSIONS: Among patients with suspected sarcoidosis and evidence of myocardial inflammation, treatment response by serial FDG-PET was variable, but a favorable response was more common when using moderate-to-high intensity prednisone dose. Biopsy-proven individuals and those with preserved systolic function were less likely to experience adverse outcomes during follow-up.
引用
- Rojulpote, Bhattaru, Jean, et al. Effect of Immunosuppressive Therapy and Biopsy Status in Monitoring Therapy Response in Suspected Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2022. PMID: 36357136. doi:10.1016/j.jcmg.2022.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。